| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 80, 2282-2288, Copyright © 1995 by Endocrine Society
ARTICLES |
A Bereket, CH Lang, SL Blethen, J Fan, RA Frost and TA Wilson
Department of Pediatrics, State University of New York at Stony Brook 11794-8111, USA.
Limited proteolysis of serum insulin-like growth factor (IGF) binding protein (IGFBP)-3 has been described in various conditions and may increase the bioavailability of IGFs. The physiological regulators of serum IGFBP-3 protease activity are unknown. To characterize the relationship between insulin and IGFBP-3 protease activity, we have examined serum IGFBP-3 proteolysis in children with untreated insulin- dependent diabetes mellitus (IDDM) and have followed the effect of insulin therapy on serum IGFBP-3 proteolysis at 1 day, 1 week, and 1 month after the initiation of insulin therapy. Ligand blot analysis of sera from untreated children with IDDM showed that intact IGFBP-3 was 50 +/- 9% of the age-matched control pool. After the initiation of insulin treatment, IGFBP-3 did not change significantly at 1 day after treatment but increased dramatically at 1 week (90 +/- 13%) and 1 month after treatment (102 +/- 13%). In contrast, when measured by immunoradiometric assay (which detects both intact and fragments of IGFBP-3), IGFBP-3 levels were 70% of the control pool before insulin therapy and did not increase significantly until 1 month after treatment. Immunoblot analysis demonstrated that intact IGFBP-3 doublet was diminished to 41 +/- 7% of controls, whereas the major IGFBP-3 fragment (30 kDa) was increased in IDDM sera before insulin therapy. After insulin, intact IGFBP-3 increased and the 30-kDa fragment decreased to values comparable to those observed in controls. In vivo IGFBP-3 proteolysis, which implies preassay exposure of serum IGFBP-3 to proteases, was estimated by immunoblot analysis. IGFBP-3 proteolysis was increased before insulin therapy (160 +/- 9%) and decreased to 81 +/- 9% at 1 week and to 71 +/- 11% at 1 month after insulin treatment. Residual serum IGFBP-3 protease activity was estimated by a 125I-IGFBP- 3 degradation assay. Serum IGFBP-3 protease activity increased significantly in untreated diabetics, compared with activity in controls (128 +/- 5% vs. 99 +/- 11%). During insulin therapy, serum IGFBP-3 protease activity decreased gradually to 91 +/- 5% of control values at 1 month. Molecular sizes of the IGFBP-3 proteolytic fragments (30 kDa, 24 kDa, and 19 kDa) and inhibition profile of IGFBP-3 protease were similar in IDDM and pregnancy sera, indicating that similar proteases (cation-dependent serine proteases) were active in both conditions. These results suggest an important role of insulin in the regulation of IGFBP-3 protease activity. Increased IGFBP-3 proteolysis in the sera of children with IDDM may serve to counteract the catabolic state induced by insulin deficiency.
This article has been cited by other articles:
 |
|
 |
|
  Q. Zhou, L.-Z. Liu, B. Fu, X. Hu, X. Shi, J. Fang, and B.-H. Jiang Reactive oxygen species regulate insulin-induced VEGF and HIF-1{alpha} expression through the activation of p70S6K1 in human prostate cancer cells Carcinogenesis, January 1, 2007; 28(1): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Moller, S. P. Jorgensen, J.-W. Chen, A. Larnkjaer, T. Ledet, A. Flyvbjerg, and J. Frystyk Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro. Eur. J. Endocrinol., August 1, 2006; 155(2): 297 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Clemmons, M. Sleevi, and W. H. Busby Jr. Recombinant, Nonglycosylated Human Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) Is Degraded Preferentially after Administration to Type II Diabetics, Resulting in Increased Endogenous Glycosylated IGFBP-3 J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6561 - 6568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saukkonen, R. Amin, R. M. Williams, C. Fox, K. C. Yuen, M. A. White, A. M. Umpleby, C. L. Acerini, and D. B. Dunger Dose-Dependent Effects of Recombinant Human Insulin-Like Growth Factor (IGF)-I/IGF Binding Protein-3 Complex on Overnight Growth Hormone Secretion and Insulin Sensitivity in Type 1 Diabetes J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4634 - 4641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Silfen, M. R. Denburg, A. M. Manibo, R. A. Lobo, R. Jaffe, M. Ferin, L. S. Levine, and S. E. Oberfield Early Endocrine, Metabolic, and Sonographic Characteristics of Polycystic Ovary Syndrome (PCOS): Comparison between Nonobese and Obese Adolescents J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4682 - 4688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Norrelund, J. Frystyk, J. O. L. Jorgensen, N. Moller, J. S. Christiansen, H. Orskov, and A. Flyvbjerg The Effect of Growth Hormone on the Insulin-Like Growth Factor System during Fasting J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3292 - 3298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Lauszus, J. G. Klebe, T. Bek, and A. Flyvbjerg Increased Serum IGF-I During Pregnancy Is Associated With Progression of Diabetic Retinopathy Diabetes, March 1, 2003; 52(3): 852 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nemet, Y. Oh, H.-S. Kim, M. Hill, and D. M. Cooper Effect of Intense Exercise on Inflammatory Cytokines and Growth Mediators in Adolescent Boys Pediatrics, October 1, 2002; 110(4): 681 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. de Groof, K. F. M. Joosten, J. A. M. J. L. Janssen, E. D. de Kleijn, J. A. Hazelzet, W. C. J. Hop, P. Uitterlinden, J. van Doorn, and A. C. S. Hokken-Koelega Acute Stress Response in Children with Meningococcal Sepsis: Important Differences in the Growth Hormone/Insulin-Like Growth Factor I Axis between Nonsurvivors and Survivors J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3118 - 3124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Cutfield, P. L. Hofman, M. Vickers, B. Breier, W. F. Blum, and E. M. Robinson IGFs and Binding Proteins in Short Children with Intrauterine Growth Retardation J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 235 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Fedele, C. H. Lang, and P. A. Farrell Immunization against IGF-I prevents increases in protein synthesis in diabetic rats after resistance exercise Am J Physiol Endocrinol Metab, June 1, 2001; 280(6): E877 - E885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lassarre, F. Duron, and M. Binoux Use of the Ligand Immunofunctional Assay for Human Insulin-Like Growth Factor (IGF) Binding Protein-3 (IGFBP-3) to Analyze IGFBP-3 Proteolysis and IGF-I Bioavailability in Healthy Adults, GH-Deficient and Acromegalic Patients, and Diabetics J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1942 - 1952. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. F. LAUSZUS, J. G. KLEBE, and A. FLYVBJERG Macrosomia Associated With Maternal Serum Insulin-Like Growth Factor-I and -II in Diabetic Pregnancy Obstet. Gynecol., May 1, 2001; 97(5): 734 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Fedele, T. C. Vary, and P. A Farrell Plasticity in Skeletal, Cardiac, and Smooth Muscle: Selected Contribution: IGF-I antibody prevents increases in protein synthesis in epitrochlearis muscles from refed, diabetic rats J Appl Physiol, March 1, 2001; 90(3): 1166 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Helle, T. Ueland, D. Ekse, S. S. Frøland, J. M. P. Holly, P. E. Lønning, and P. Aukrust The Insulin-Like Growth Factor System in Human Immunodeficiency Virus Infection: Relations to Immunological Parameters, Disease Progression, and Antiretroviral Therapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 227 - 233. [Abstract] [Full Text]
|
|
|
|
|
|
S. Cianfarani, R. Bonfanti, M. L. M. Bitti, D. Germani, S. Boemi, G. Chiumello, and B. Boscherini Growth and Insulin-Like Growth Factors (IGFs) in Children with Insulin-Dependent Diabetes Mellitus at the Onset of Disease: Evidence for Normal Growth, Age Dependency of the IGF System Alterations, and Presence of a Small (Approximately 18-Kilodalton) IGF-Binding Protein-3 Fragment in Serum J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4162 - 4167. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. R. Devi, D.-H. Yang, R. G. Rosenfeld, and Y. Oh Differential Effects of Insulin-Like Growth Factor (IGF)-Binding Protein-3 and Its Proteolytic Fragments on Ligand Binding, Cell Surface Association, and IGF-I Receptor Signaling Endocrinology, November 1, 2000; 141(11): 4171 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shinada, A. Akdeniz, S. Panagiotopoulos, G. Jerums, and L. A. Bach Proteolysis of Insulin-Like Growth Factor-Binding Protein-3 Is Increased in Urine from Patients with Diabetic Nephropathy J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1163 - 1169. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Fedele, J. M. Hernandez, C. H. Lang, T. C. Vary, S. R. Kimball, L. S. Jefferson, and P. A. Farrell Severe diabetes prohibits elevations in muscle protein synthesis after acute resistance exercise in rats J Appl Physiol, January 1, 2000; 88(1): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Maile, S. Xu, S. C. Cwyfan-Hughes, J. K. Fernihough, J. M. Pell, and J. M. P. Holly Active and Inhibitory Components of the Insulin-Like Growth Factor Binding Protein-3 Protease System in Adult Serum, Interstitial, and Synovial Fluid Endocrinology, December 1, 1998; 139(12): 4772 - 4781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Skjærbæk, A. Kaal, J. Møller, N. Vahl, J. Weeke, H. Ørskov, and A. Flyvbjerg No Effect of Growth Hormone on Serum Insulin-Like Growth Factor Binding Protein-3 Proteolysis J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1206 - 1210. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z. Shi, W. Xu, F. Loechel, U. M. Wewer, and L. J. Murphy ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3 J. Biol. Chem., June 9, 2000; 275(24): 18574 - 18580. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
